L’Oréal Eyes Aesthetics Market with Acquisition of Minority Stake in Galderma 

Major beauty brand L’Oréal announced the acquisition of a 10% stake in Galderma, a Swiss pharmaceutical company. The two companies have agreed to work towards a strategic scientific partnership that will leverage the undisputed expertise of both companies, according to a press release. 

L’Oréal’s CEO Nicolas Hieronimus says the investment and partnership marks an “ambitious step” for L’Oréal to enter the “fast-growing aesthetics market.” 

“We fully support Galderma’s management and its strategy as a leading dermatology pure player, respect its independence and are very confident in its long-term growth potential,” Hieronimus said. 

The investment in Galderma confirms the solid growth journey that L’Oréal has embarked on over the past decade with goals of investing in a more holistic approach, spanning across the entire beauty routine. 

Galderma has established itself as they “pure-play” dermatology category leader and one of the world’s largest players in injectable aesthetics. Galderma offers a broad portfolio of dermo-cosmetics, dermatologic drugs, and best-in-class hyaluronic acid fillers, neuromodulators, and biostimulators. 

The stake of the company is being acquired from Sunshine SwissCo AG, a consortium led by EQT, Abu Dhabi Investment Authority, and Auba Investment Pte. Ltd. 

The financial details of the deal have not been disclosed. 

Galderma supports the transaction and the partnership of L’Oréal. L’Oréal will not seek to be represented at Galderma’s Board of Directors and has agreed to customary provisions for an investment of this type as part of a shareholders’ agreement entered into with Sunshine SwissCo AG.